Zobrazeno 1 - 10
of 64
pro vyhledávání: ''
Autor:
Hiroshi Tsubamoto, Y Takimoto, Tomoko Ueda, Hiroaki Shibahara, R Isono, Masakazu Shinohara, Kayo Inoue, Kazuko Sakata
Publikováno v:
Anticancer Research. 41:4271-4276
Background/aim The anticancer mechanism of itraconazole remains unsolved; therefore, we studied itraconazole-induced alterations in specialized pro-resolving mediators (SPMs) in cancer cells. Materials and methods The human cervical squamous carcinom
Publikováno v:
Anticancer Research. 41:3769-3778
BACKGROUND/AIM Cholangiocarcinoma is a lethal disease with increasing incidence worldwide. New therapeutic compounds are urgently needed for this disease. Here, the inhibitory effect of adenosine on cholangiocarcinoma cells was studied. MATERIALS AND
Autor:
Christian Thomas, Nadine Gelbrich, Alexander Mustea, Matthias B Stope, Maria A Oster, Holger H.H. Erb, Clemens Cammann
Publikováno v:
Anticancer Research. 41:3271-3279
Background/aim Androgen receptor (AR) degradation is the primary regulator of androgen receptor activity. This study was designed to investigate the influence of the proteasome on AR protein stability after enzalutamide (Enz) treatment. Materials and
Publikováno v:
Anticancer Research. 41:2945-2952
Aim To evaluate the effects of the combination of calcitriol and chemotherapy and to identify the molecular mechanisms underlying the effect of calcitriol on ovarian cancer cells. Materials and methods SKOV-3 cells were treated with calcitriol and ci
Publikováno v:
Anticancer Research. 41:2795-2804
Background/aim Neuroblastoma is the most common childhood extracranial solid malignancy. Although cancer cells need iron and lipids for active cell division, possible links between iron and lipid metabolism in neuroblastomas have not been studied. Ma
Autor:
Fei-Ting Hsu, Bo-Siang Fu, Ching-Hsuan Wu, Mao-Chi Weng, Jai-Jen Tsai, Po-Jung Pan, Kung-Hung Lin
Publikováno v:
Anticancer Research. 41:1251-1259
Background/aim Sorafenib, an oral multi-kinase inhibitor, has been shown to improve the outcome of patients with osteosarcoma (OS). However, the anti-OS effect and mechanism of sorafenib has not yet been fully understood. The main purpose of this stu
Autor:
Youngki Lee, Deok-Bae Park
Publikováno v:
Anticancer Research. 41:1387-1399
Background/aim Despite clinical benefit from treatment with dabrafenib and trametinib in melanoma patients with BRAF mutations, half relapse within months and one-third are unresponsive to treatment. We evaluated the anticancer potential of metformin
Autor:
Walburgis Brenner, Marco Johannes Battista, Amelie Loewe, Anne-Sophie Heimes, R Schwab, Annette Hasenburg, Slavomir Krajnak, Marcus Schmidt
Publikováno v:
Anticancer Research. 41:1243-1250
Background/aim Breast cancer (BC) may be affected by diabetes and anti-diabetic medication, as well as its therapeutic agents. Low-dose metronomic chemotherapy (LDMC) is an available treatment option in BC. We investigated the impact of insulin on lo
Autor:
Hyun Jung Kim, Kyun Heo
Publikováno v:
Anticancer Research. 41:671-678
Background/aim Hepatocyte growth factor (HGF) acts as a key regulator in promoting ovarian cancer metastasis. Previously, we observed that YYB-101, a humanized anti-HGF antibody, effectively inhibits ovarian cancer cell migration, invasion, and progr
Autor:
Zhao Lin Tan, Yuan Hao Lee, Fei Ting Hsu, Chia Jung Tsai, Yi Chi Huang, Ta Chih Liu, Cheng Hsien Chen, Yao Chen Chuang, Hsi Feng Tu
Publikováno v:
Anticancer Research. 40:6723-6732
Background/aim Nuclear factor kappa B (NF-κB) inactivation and apoptosis activation have been shown to enhance the anticancer effect of cisplatin in oral squamous cell carcinoma (OSCC). Amentoflavone may suppress NF-κB activity and trigger apoptosi